Archive for May, 2007
May 31st, 2007. Diagnostic biomarker of asbestos-related mesothelioma: Example of translational research
Asbestos-related mesothelioma should be ascribed as a typical environmental carcinogen. In this review, we will present asbestos-related mesothelioma for the study of problems in environmental carcinogenesis.
May 31st, 2007. Registration of selected cases of occupational cancer (1994-2002) with the Danish National Board of Industrial Injuries
Conclusion: We observed a substantial underreporting of pleural mesothelioma and adenocarcinoma of the sinonasal cavities with the National Board of Industrial Injuries. The underreporting seemed to be unchanged since the 1980s. We propose that all cases of mesothelioma and all cases of cancer of the sinonasal cavities not registered with the Board are referred to a department for industrial medicine for etiological evaluation.
May 31st, 2007. The risk of mesothelioma from exposure to chrysotile asbestos
Although scientific efforts and legal arguments continue, the risk of pleural mesothelioma in human populations is probably negligible for exposures to airborne chrysotile asbestos that is not known to be contaminated by amphibole. This distinction for asbestos fiber types is pivotal for understanding hazards and characterizing risks of continued use of natural chrysotile asbestos today and also new nanofibers.
May 31st, 2007. Biomarkers for mesothelioma
Elevated SMRP levels raise suspicion of mesothelioma although negative values do not exclude disease. Its role in disease monitoring in patients and in predicting disease development in at-risk individuals warrant further study.
May 26th, 2007. The Rochdale asbestos cancer studies and the politics of epidemiology: what you see depends on where you sit
asbestos industry and the subsequent obscuring of the disastrous results of exposures is presented, exploring in particular the roles of Sir Richard Doll and his colleagues. Epidemiology, often regarded as a neutral science, is susceptible to socio-political influences.
May 25th, 2007. Evidence-based guidelines for the utilization of immunostains in diagnostic pathology: pulmonary adenocarcinoma versus mesothelioma
19) that were equal or better in efficacy when compared with more comprehensive panels. These results support the potential value of systematic reviews, meta-analysis, and OR calculations for development of EBG in diagnostic immunohistology.
May 25th, 2007. Management options for malignant pleural mesothelioma: clinical and cost considerations
Ongoing clinical trials are comparing chemotherapy and surgery with supportive care in an effort to define the role of different therapies in MPM. MPM treatment is a costly public health issue; after efficacy is proven, additional studies are needed to measure the cost effectiveness of MPM treatment regimens.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Full Archive, New & Novel, Pemetrexed (Alimta), Pleural, Survival, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
May 25th, 2007. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma
Bortezomib may improve outcome in MPM patients alone or in combination with standard chemotherapy but the order of administration is likely to be important. This study justifies further evaluation of bortezomib in MPM.
May 24th, 2007. Severe cutaneous toxicity after Pemetrexed as second line treatment for a refractory non small cell lung cancer
Conclusion: Cutaneous toxicity from pemetrexed should be recognised on account of its potential severity. The appearance of skin lesions is an indication for careful follow-up for evidence of Lyell's syndrome for which intensive management is needed.
May 22nd, 2007. Some Limitations of Aggregate Exposure Metrics
Under these conditions, which are not uncommon in practice, aggregate exposure metrics may be "worse than useless," in that risk-management decisions based on them are less effective than decisions that ignore the aggregate exposure information and select risk-management actions at random. The potential practical significance of these results is illustrated by a case study of 27 exposure scenarios in El Dorado Hills, California, where applying an aggregate unit risk factor (from EPA's IRIS database) to aggregate exposure metrics produces average risk estimates about 25 times greater—and of uncertain predictive validity—compared to risk estimates based on specific components of the mixture that have been hypothesized to pose risks of human lung cancer and mesothelioma.
May 22nd, 2007. Low prevalence of SV40 in Swiss mesothelioma patients after elimination of false-positive PCR results
SV40 DNA and protein were found at low prevalence (5%) in plasma and tumour tissue, respectively. This suggests that SV40 does not appear to play a major role in the development of mesothelioma.
May 22nd, 2007. A preliminary experimental study of boron neutron capture therapy for malignant tumors spreading in thoracic cavity
Conclusions: BNCT is a potentially promising treatment for malignant tumors spreading in the thoracic cavity such as MPM.
May 18th, 2007. Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial
An interim analysis will be conducted after 700 patients have been enrolled. The study will also use pharmacogenomic analysis to evaluate biological predictors of response, in particular to pemetrexed.
May 18th, 2007. SYT-SSX fusion is absent in sarcomatoid mesothelioma allowing its distinction from synovial sarcoma of the pleura
Molecular analysis completed in two independent laboratories showed that sarcomatoid mesothelioma samples were negative for the t(X-18). This result confirms the usefulness of this analysis in differentiating sarcomatoid mesothelioma from synovial sarcoma.
May 17th, 2007. Asbestos-related cancers in refinery workers in the Australian petroleum industry
Lung cancer rates in refinery workers did not increase with duration of employment; however, they did tend to be higher in workers hired in earlier decades. Excess mesothelioma incidence in refinery workers is confirmed, but it is likely that there are few if any asbestos-related lung cancers.
May 17th, 2007. Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment
Conclusions: Osteopontin has a lower diagnostic accuracy than mesothelin in patients suspected of MPM. Insufficient specificity limits osteopontin utility as diagnostic marker. Both molecules have a potential value as prognostic markers.
May 15th, 2007. Intracavitary mass as the initial manifestation of primary pericardial mesothelioma: a case report
Significant amounts of pleural fluid and huge tumors within both pleural cavities emerged. The patient died due to respiratory and circulatory insufficiency 11 months following the diagnosis.
Posted in Biphasic or Mixed, Carboplatin, Case Study, Chemotherapy, Diagnosis & Differentiation, Full Archive, Gemcitabine (Gemzar), Immunohistochemistry or IHC, Pleural, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
May 15th, 2007. A 56-year mortality follow-up of Texas petroleum refinery and chemical employees, 1948-2003
Conclusions: After more than half a century of follow-up, employees at this facility continue to show more favorable mortality outcomes than the general local population. Overall, no statistically significant increase of leukemia or of any of the specific cell types was found. The increased mesothelioma is likely related to past exposure to asbestos.
May 15th, 2007. Eighth International Mesothelioma Interest Group
Here, experts in different disciplines critically review some of the most exciting presentations of the IMIG meeting. The result is a comprehensive review of the research field of asbestos carcinogenesis and mesothelioma, and of the progress that has been made in recent years in both basic and clinical sciences.
|
|  |
